Evidence map›Paper›PMID 26149894›Full record

ArticleAIDS research and human retroviruses2015

Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.

Yehuda Z Cohen, Christy L Lavine, Caroline A Miller, Jetta Garrity, Brittany R Carey, Michael S Seaman

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yehuda Z CohenCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
Christy L LavineCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
Caroline A MillerCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
Jetta GarrityCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
Brittany R CareyCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
Beth Israel Deaconess Medical Center · US

Funding

Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
NIAID NIH HHS T32 AI007387
6 · The paper itself

Abstract

A number of potent broadly neutralizing antibodies against HIV-1 have recently been identified that target epitopes on the viral envelope that contain N-linked glycans. It remains unknown how frequently glycan-dependent neutralizing antibodies generally arise during the course of natural infection or whether particular glycosylation sites are preferentially targeted. We tested sera with a broad range of neutralization activity from individuals infected with HIV-1 clades B or C against panels of HIV-1 Env pseudoviruses that lacked specific glycans in the outer domain glycan cluster (ODGC) or inner domain glycan cluster (IDGC) to determine the presence of glycan-dependent neutralizing antibodies. Overall, 54% of individuals were observed to have neutralizing antibodies targeting these glycan regions. Glycan-specific neutralizing antibodies were readily detected in sera that were selected for having broad, moderate, or weak neutralization potency and breadth. Our results demonstrate that glycan-specific neutralizing antibodies arise with appreciable frequency in individuals chronically infected with HIV-1 clades B and C. Antibody responses that commonly occur during natural infection may be more feasible to induce by vaccination; thus glycan-specific neutralizing antibodies may be desirable responses to elicit with candidate HIV-1 vaccines.

Indexed as

GenotypeAntibodies, NeutralizingHIV-1HIV AntibodiesHIV InfectionsPolysaccharidesAntibodies, NeutralizingHIV AntibodiesPolysaccharides

Identifiers

PMID26149894
PMCPMC4651021
OpenAlexW1746380928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.